ONO Pharmaceutical Co., Ltd. 4528

Ono Pharmaceutical Co. (OPHLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aitia will use its platform to analyse clinical and omics data and construct digital models for predictions.

The partnership gives Ono the exclusive option to license worldwide rights to develop the therapeutic programmes.

Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, has entered into a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") for novel treatments targeting fibro-inflammatory diseases. These diseases are characterized by myofibroblast activation, scarring, inflammation and tissue remodeling, which can lead to organ failure and compli

Ono Pharmaceutical (TSE:4528) has drawn fresh attention after reporting first quarter results to June 30, 2026, with sales of ¥116,160 million and net income of ¥24,151 million. See our latest analysis for Ono Pharmaceutical. Despite the stronger first quarter earnings, Ono Pharmaceutical’s recent share price momentum has softened, with the 7 day share price return down 7.65% and the 30 day share price return down 6.02%. However, the 1 year total shareholder return of 39.96% still reflects a...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ono Pharmaceutical Co. (OPHLF) delivered earnings and revenue surprises of +60.00% and +5.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ono Pharmaceutical Co., Ltd. (TYO: 4528, "Ono") and Phylo, Inc. ("Phylo") today announced a collaboration that brings Biomni Lab, Phylo's agentic AI platform for biomedical research, to Ono's drug discovery scientists.

Ono Pharmaceutical Co. (OPHLF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ono Pharmaceutical Co. (OPHLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

WALTHAM, Mass., June 17, 2026--Deciphera Pharmaceuticals, LLC, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), announced the first patient was dosed in the global pivotal Phase 3 INTREPID study evaluating sapablursen for the treatment of polycythemia vera (PV). Sapablursen is an investigational drug that has the potential to offer a once-monthly treatment option for patients with PV, a rare and potentially life-threatening hematolog

Key market opportunities in thyroid cancer therapeutics include China's anticipated rise in cases through 2029, the growing importance of targeted therapies and emerging immunotherapies, a robust pipeline with 119 molecules including significant Phase III assets, and active M&A and strategic alliances enhancing market dynamics.Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Thyroid Cancer (TC): Market View" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-dri

The polycythemia vera market is set for expansion by 2036, as new entrants such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ionis Pharmaceuticals and Ono Pharmaceutical (sapablursen), Silence Therapeutics (Divesiran (SLN124)), Perseus Proteomics (PPMX-T003), Disc Medicines (DISC-3405), and others are evaluating their lead candidates in different stages of clinical development, respectively.New York, USA, April 22, 2026 (GLOB

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best growth stocks to buy according to billionaires. As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street. Based on 21 analyst targets, the average price target stood at $89.00, with a high target of $110.00 and a low target […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its fiscal Q4 and full-year 2025 earnings on February 25, reporting that total revenue for the year ended December 31, 2025, was $944 million compared to $705 in the previous year, considerably surpassing expectations […]